menu
    • menu
    [{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Beyond Air","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Beyond Air"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Stanford Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Stanford Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Stanford Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Beyond Cancer

    Menu

    Beyond Cancer

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beyond Cancer Starts Phase 1b Trial with LV UNO and Anti-PD-1 in Israel

                            Details : LV UNO (nitric oxide) is a soluble guanylate cyclase activator, which is currently being evaluated for the treatment of cancers.

                            Product Name : LV UNO

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beyond Cancer„¢ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable...

                            Details : UNO (nitric oxide) is a potent molecule, naturally synthesized in the human body. It is being evaluated in phase 1 clinical trials for advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors.

                            Product Name : UNO

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 27, 2023

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Stanford Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, M...

                            Details : Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer.

                            Product Name : UNO

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Stanford Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Meth...

                            Details : Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.

                            Product Name : UNO

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2022

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beyond Cancer Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Show...

                            Details : Data suggests ultra-high concentration gaseous Nitric oxide (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response.

                            Product Name : UNO

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2022

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Beyond Air

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placem...

                            Details : Beyond Cancer, including those owned by Beyond Air, will use the proceeds from the private placement for the safety and efficacy of the ultra-high concentration nitric oxide product, as well as its therapeutic potential in a number of indications.

                            Product Name : UNO

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Beyond Air

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth